Clinical trial
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab)…
NCT02684370 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT02684370 |
|---|---|
| Title | BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis |
| Official title | BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1) |
| Lead sponsor | AbbVie, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | risankizumab, placebo for risankizumab, ustekinumab, placebo for ustekinumab |
| Enrollment | 560 |
| Start date | Feb 1, 2016 |
| Primary completion | Dec 1, 2016 |
| Completion | Sep 1, 2017 |
| First posted | Feb 18, 2016 |
| Last update posted | Jul 30, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: